Behind the Scenes of Global Regulatory Submission Planning is a Symphony of Collaboration 

What does it really take to get a regulatory submission across the finish line? It’s more than documents and deadlines, it is a finely tuned performance built on planning, precision, and partnership. Behind every submission is a dynamic ensemble of expertise from Project Management, Biometrics, Medical Writing, and Quality Control. 

From onboarding teams with essential tools and processes to synchronizing timelines, clarifying roles and mitigating risks, early preparation sets the tempo for success. Biostatisticians and medical writers work in harmony to transform complex data into a polished composition, while quality control provides a steady rhythm of accuracy and compliance—not as a closing act, but as an integral part of the entire piece.  

In this article, MMS pulls back the curtain to reveal how these functions harmonize efforts, share best practices, and overcome challenges to deliver global regulatory submissions that crescendo into excellence. 

The View from Biostatistics 

A thorough gap analysis is one of the earliest and most critical steps in preparing an ISS/ISE FDA regulatory submission. From a biostatistics perspective, this is like tuning the instruments before the performance, systematically evaluating existing clinical data, statistical outputs, and documentation against current regulatory requirements.  

The goal is to identify missing analyses, inconsistencies across studies, and any data quality or traceability issues that could compromise the integrated evidence package for regulatory submissions. Conducting this analysis early helps set the tempo for remediation activities, align analytical strategies, and minimize surprises during integration and submission. 

Alignment between the integrated summary of safety and efficacy (ISS/ISE) and individual study SAPs and CSRs ensures that the regulatory submission plays as a cohesive piece. While each study follows its own SAP, the integrated analyses require dedicated ISS/ISE SAPs that define the integration strategy, analysis populations, statistical methods, and approaches for handling cross-study issues such as variable harmonization and missing data. Establishing this alignment early prevents methodological discord, reduces rework, and ensures the integrated analyses present a clear, unified narrative that meets regulatory expectations. 

A well-justified data pooling strategy is fundamental to ISS/ISE preparation. This includes demonstrating that clinical studies being combined are sufficiently similar in design, patient populations, endpoints, and treatment regimens to support meaningful integrated analyses. The regulatory strategy should clearly define inclusion and exclusion criteria for studies and subjects, along with rationale for these decisions. Addressing heterogeneity between studies, such as differences in dosing schedules, endpoint definitions, or demographic distributions, through stratification, sensitivity analyses, or model-based approaches ensures statistical soundness and credibility of pooled results. 

Finally, consistency in endpoint definitions, handling of missing data, and subgroup analyses are critical components of integration. Harmonizing derived variables across clinical studies prevents artificial variability and strengthens interpretability. Missing data must be managed using standardized imputation strategies and supported by sensitivity analyses to assess robustness. Subgroup analyses should be pre-specified and carefully interpreted, with interaction tests performed where appropriate. Together, these steps ensure that the integrated evidence package performs with precision and balance, delivering a regulatory submission that strikes the right chord with global health authorities. 

The View from Medical Writing 

Medical Writing’s role in submission planning and execution is not only to accurately describe drug manufacturing, nonclinical and clinical studies, and their data, but also to ensure the sponsor’s key messaging resonates clearly with regulators. To achieve this, the overall medical writing lead and document leads must establish expectations—both at the submission level and for individual documents—before the first note of medical writing begins. 

Considerable preparation happens during the Kick-Off Meeting (KOM), a pivotal moment to set the tempo for success. These sessions align teams on regulatory deliverables, timelines, and communication protocols. Whether confirming sponsor-specific templates and style guides, identifying core reviewers, or clarifying risks, transparency from the outset ensures everyone is playing from the same score. Reviewing previous regulatory submissions can further inform the approach and anticipate sponsor preferences. By proactively defining roles, responsibilities, and escalation pathways, the team avoids discord and fosters a collaborative rhythm that supports efficient, high-quality document delivery. 

Another essential element is the Consistency Guide, a living document that keeps the melody consistent across all regulatory submission materials. Established early, it captures key messaging, approved terminology, stylistic preferences, and formatting standards, serving as a central reference point for contributors. As projects evolve, the guide should be updated to reflect new decisions and feedback, ensuring every document speaks in harmony and meets both internal and sponsor standards. 

Internal and external meetings act as recurring refrains, maintaining alignment and momentum throughout the process. These touchpoints allow crosstalk between documents, ensuring updates in one area echo across the regulatory submission. Workstream Meetings with clients provide a focused space to fine-tune messaging and address challenges early, while also functioning as status check-ins to monitor readiness and adjust timelines. As documents near finalization, this coordination becomes even more critical, helping teams manage dependencies and preserve quality.  

By leveraging these collaborative moments effectively, Medical Writing helps orchestrate a regulatory submission that concludes with clarity, precision, and a performance worthy of applause. 

The View from Quality Control 

A strong QC strategy begins with precise, forward-looking planning, setting the tempo well before the regulatory submission deadline approaches. QC leads collaborate with project managers and medical writers to map when each eCTD document will be ready for review and how long its QC will realistically take. This careful scheduling accounts for review cycles and sponsor feedback ensuring QC is not rushed in a last-minute crescendo. Early inclusion of the QC lead in regulatory submission team meetings provides visibility and understanding of the full submission timeline and helps identify documents that might need special attention or areas where consistency checks across modules are particularly critical. 

Resourcing QC colleagues is just as vital. At a data-focused CRO, QC reviewers are assigned based on experience with document type, length, and complexity, factoring in benchmark hours and whether multiple reviewers are needed. For large, high-impact documents like the prose-based summary modules, QC leads may deploy additional reviewers or plan for a final “consistency pass” to harmonize repeated sections and ensure messaging stays in tune across the dossier. This strategic staffing helps maintain both quality and pace. 

To keep QC running smoothly, medical writers provide documents to QC as a complete toolkit: source tables and figures, annotated outputs, relevant templates, and a living consistency guide capturing sponsor preferences and evolving decisions. Some review work begins even before documents are finalized, as early drafts may undergo informal checks to catch issues upstream. And when timelines tighten, contingency plans like parallel QC or re-use of pre-approved content blocks help maintain rhythm without sacrificing rigour.  

QC ensures that, whether the piece follows the original score or calls for an impromptu variation, the final performance resonates with clarity and confidence. The goal is simple: anticipate where we can, adapt where we must, and keep the regulatory submission in harmony, even when the tempo changes. By striking the right balance between precision and agility, QC helps deliver a regulatory submission that stands out for its quality and consistency. 

Bringing a regulatory submission to life is never a solo performance, it’s a symphony of collaboration. From Project Management setting the tempo, to Medical Writing shaping the narrative, Biostatistics ensuring methodological harmony, and Quality Control fine-tuning every detail, each function plays a distinct yet interconnected part. Success depends on anticipating challenges, adapting when the unexpected arises, and maintaining alignment so the final composition resonates properly. When these disciplines work in concert, the result is more than a regulatory submission—it’s a performance that earns applause for its quality and integrity. 

For questions related to this article, message us here.  

This article was drafted by James Newman, Louise Van Aswegen, Daniela Gula, and Natalie Pizzimenti.